<SEC-DOCUMENT>0001648257-25-000083.txt : 20251208
<SEC-HEADER>0001648257-25-000083.hdr.sgml : 20251208
<ACCEPTANCE-DATETIME>20251208060253
ACCESSION NUMBER:		0001648257-25-000083
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251208
FILED AS OF DATE:		20251208
DATE AS OF CHANGE:		20251208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUTCHMED (China) Ltd
		CENTRAL INDEX KEY:			0001648257
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37710
		FILM NUMBER:		251554522

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3
		BUSINESS PHONE:		852-2121-3888

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		48TH FLOOR, CHEUNG KONG CENTER
		STREET 2:		2 QUEEN'S ROAD CENTRAL
		CITY:			HONG KONG
		PROVINCE COUNTRY:   	K3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Hutchison China MediTech Ltd
		DATE OF NAME CHANGE:	20150716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>hcm-20251208x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 12/8/2025 09:20:13 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;text-align:right;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt 1.5pt 0pt 0pt;"><font style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">FORM&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:16pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:18pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Month of </b><b style="font-weight:bold;">December</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">2025</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number: 001-37710</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Translation of registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">48th Floor, Cheung Kong Center, 2 Queen&#8217;s Road Central, Hong Kong</b> </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1.2" width="25.0%" style="background-color:#000000;color:#000000;height:1.2pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#160;20-F or Form&#160;40-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Form&#160;20-F&#160;&#160;<font style="font-family:'Times New Roman';">&#8999;</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;<font style="font-family:'Times New Roman';">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">HUTCHMED (CHINA) LIMITED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form&#160;6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT&#160;INDEX</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:11.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:87.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:11.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:87.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:11.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exhibit 99.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin:0pt 36pt 0pt 0pt;"><font style="font-weight:normal;">Press release </font><font style="font-weight:normal;">relating</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">to</font><font style="font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-weight:normal;letter-spacing:-0.1pt;">e</font><font style="font-weight:normal;letter-spacing:-0.1pt;">xpanded </font><font style="font-weight:normal;letter-spacing:-0.1pt;">c</font><font style="font-weight:normal;letter-spacing:-0.1pt;">overage on National Reimbursement Drug List and </font><font style="font-weight:normal;letter-spacing:-0.1pt;">i</font><font style="font-weight:normal;letter-spacing:-0.1pt;">nclusion in the </font><font style="font-weight:normal;letter-spacing:-0.1pt;">f</font><font style="font-weight:normal;letter-spacing:-0.1pt;">irst Commercial Insurance Drug List in China</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:9.55pt;"><td style="vertical-align:top;width:11.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">HUTCHMED (CHINA) LIMITED</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:41.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">/s/ Johnny Cheng</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:41.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Johnny Cheng</p></td></tr><tr><td style="vertical-align:top;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:41.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Chief Financial Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Date: December 8, 2025</p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:10pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>hcm-20251208xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 12/8/2025 09:20:13 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:32.3%;">&#9;</font><font style="display:inline-block;width:11.76%;">&#9;</font><font style="display:inline-block;width:38.55%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">Exhibit 99.1</b></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><img src="hcm-20251208xex99d1001.gif" alt="Graphic" style="display:inline-block;height:44.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:160.15pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="white-space:pre-wrap;">                                              </font><font style="font-size:12pt;white-space:pre-wrap;">                                                                                                          </font><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk181768051"></a><b style="font-weight:bold;">Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk181710291"></a><b style="font-size:12pt;font-weight:bold;">HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Hong Kong, Shanghai &amp; Florham Park, NJ &#8212; Monday, December 8, 2025:</b> HUTCHMED (China) Limited (&#8220;HUTCHMED&#8221;) (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) today announces that following the contract renewal with the China National Healthcare Security Administration (&#8220;NHSA&#8221;), the updated National Reimbursement Drug List (&#8220;NRDL&#8221;) effective on January 1, 2026 will continue to include <font style="letter-spacing:-0.2pt;">ELUNATE</font><sup style="font-size:8.25pt;letter-spacing:-0.2pt;vertical-align:top;">&#174;</sup>, <font style="letter-spacing:-0.2pt;">ORPATHYS</font><sup style="font-size:8.25pt;letter-spacing:-0.2pt;vertical-align:top;">&#174;</sup><font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.2pt;"> &#160;SULANDA</font><sup style="font-size:8.25pt;letter-spacing:-0.2pt;vertical-align:top;">&#174;</sup><font style="letter-spacing:-0.2pt;">.</font> In addition, TAZVERIK<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup> will be included in the first edition of the National Commercial Health Insurance Innovative Drug List (&#8220;Commercial Insurance Drug List&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:2pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ELUNATE</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> (fruquintinib) </b>is included for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, in combination with TYVYT<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup> (sintilimab injection). It is also renewed for the treatment of patients with metastatic colorectal cancer who have previously received fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy, and those who have previously received or are not suitable for receiving anti-VEGF therapy or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild-type). </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">ORPATHYS</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-weight:bold;">&#160;(savolitinib) </b>is included for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping alteration.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">SULANDA</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> (surufatinib)&#160;</b>is renewed for the treatment of patients with unresectable; locally advanced or metastatic; progressive non-functional, well-differentiated (G1 or G2) pancreatic and non-pancreatic neuroendocrine tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">TAZVERIK</b><sup style="font-size:8.25pt;font-weight:bold;vertical-align:top;">&#174;</sup><b style="font-weight:bold;"> (tazemetostat)</b> is included in the Commercial Insurance Drug List for the treatment of adult patients with relapsed or refractory follicular lymphoma with <i style="font-style:italic;">EZH2</i> mutation who have received at least two prior systemic therapies. In July 2025, the NHSA issued the <i style="font-style:italic;">2025 Adjustment Work Plan for the NRDL and the&#160;Commercial Health Insurance Innovative Drug List,</i><font style="font-size:12pt;"> </font>announcing the establishment of the new Commercial Insurance Drug List. This list, together with the NRDL, forms a key component of China&#8217;s multi-level medical insurance system. This new list focuses on medicines with high innovation and significant clinical value that fall beyond the scope of basic medical insurance, including certain high-cost oncology drugs, gene therapies, and rare disease therapies, enabling reimbursement through commercial health insurance products such as high-limit medical insurance, inclusive health plans (&#8220;Huiminbao&#8221;) and group health insurance. This multi-layered reimbursement framework enhances patient access to breakthrough treatments while supporting the sustainable development of China&#8217;s innovative pharmaceutical sector.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:6pt 0pt 6pt 0pt;">About NRDL</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The government in China has placed great importance on improving the affordability of drug treatments for the public. As of end of 2024, 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the entire population. The NRDL is updated every year, and inclusion on the list is subject to renewal every two years. The NHSA annually convenes a broad network of experts in medicine, pharmacology, pharmacoeconomics and actuarial valuation to identify innovative medicines to consider for NRDL inclusion. Reimbursement of Category B medicines, including novel oncology medicines, requires varying degrees of copayment from patients, depending on their provinces or types of NHSA insurance scheme enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:6pt 0pt 6pt 0pt;">About Fruquintinib</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (&#8220;VEGFR&#8221;) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup>. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup>.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:6pt 0pt 6pt 0pt;">About Savolitinib </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib&#160;is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:6pt 0pt 6pt 0pt;">About Surufatinib</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body&#8217;s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA<sup style="font-size:8.25pt;vertical-align:top;">&#174;</sup>. HUTCHMED currently retains all rights to surufatinib worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:6pt 0pt 6pt 0pt;">About Tazemetostat</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Tazemetostat is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme, an Ipsen company. HUTCHMED entered into a strategic collaboration with Epizyme to research, develop, manufacture and commercialize tazemetostat in Chinese Mainland, Hong Kong, Macau and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:justify;margin:0pt 0pt 6pt 0pt;">About HUTCHMED</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">HUTCHMED (Nasdaq/AIM:&#8203;HCM; HKEX:&#8203;13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;">Forward-Looking Statements </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED&#8217;s current expectations regarding future events, including its expectations for the commercialization of fruquintinib, savolitinib, surufatinib and tazemetostat in China, the potential benefits and further clinical development of fruquintinib, savolitinib, surufatinib and tazemetostat, its expectations as to whether further studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the commercial acceptance of fruquintinib, savolitinib, surufatinib and tazemetostat, the impact of the inclusion of fruquintinib, savolitinib and surufatinib on the NRDL and tazemetostat on the Commercial Health Insurance Innovative Drug List on sales of the drug and its pricing, clinical trial enrollment rates, timing and availability of subjects meeting a study&#8217;s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of fruquintinib, savolitinib, surufatinib and tazemetostat to obtain regulatory approval for a targeted indication in different jurisdictions and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products&#160;such as sintilimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED&#8217;s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:italic;">Medical Information</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;">This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:always;width:91.06%;border-width:0;"><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CONTACTS</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:2.15pt 0pt 2.15pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Investor Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+852&#160;2121&#160;8200 / ir@hutch-med.com</p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Media Enquiries</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">FTI&#160;Consulting &#8211;</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+44&#160;20&#160;3727&#160;1030&#160;/ HUTCHMED@fticonsulting.com</p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">   Ben Atwell / Tim Stamper</font></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="white-space:pre-wrap;">   +44&#160;7771&#160;913&#160;902&#160;(Mobile)&#160;/ +44&#160;7421&#160;898&#160;348&#160;(Mobile)</font></p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Brunswick &#8211; Zhou Yi</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+852&#160;9783&#160;6894&#160;(Mobile)&#160;/ HUTCHMED@brunswickgroup.com</p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Panmure Liberum</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Nominated Advisor and Joint Broker</i></p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Atholl Tweedie&#160;/ Emma Earl&#160;/ Rupert Dearden</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+44&#160;20&#160;7886&#160;2500</p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cavendish</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Geoff Nash&#160;/ Nigel Birks</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+44&#160;20&#160;7220&#160;0500</p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Deutsche Numis</b></p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">Joint Broker</i></p></td></tr><tr><td style="vertical-align:top;width:39.27%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Freddie Barnfield / Jeffrey Wong / Duncan Monteith</p></td><td style="vertical-align:top;width:60.72%;margin:0pt;padding:2.15pt 0pt 2.15pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">+44 20 7260 1000</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:4.47%;margin-right:4.47%;margin-top:30pt;page-break-after:avoid;width:91.06%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>hcm-20251208xex99d1001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hcm-20251208xex99d1001.gif
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MH''GQH8Y=RX0 $H>O5XZ'! @($#KUP<PJ,G31#*! "OU%D0CP/#M"P1K0)!
M7,**Q KQN(@P0<($"$8(8E'AG'CSZM6;0R"39\OP"<VOA_^?H.)%DC9$HQ98
MG\ .0CP7#A<@<."Q0 T"3JZG?#"#_/48%332!@*L=P !8 B81P@%1B7 #@N-
MY 14J^%PFH)HT!<5 1@05$0$?X$'7@H11$?0$A+$M=9:$1PQD W,K25!&1<J
MU$6,<A6!4!TLB B>&1RI=R "N@F(P0#K147'0!O(MYH7"1VY5 $!&L1!?E$-
MD&"1=E#P'Y41YN$$EA4FE 8!!J D0(<O@BCB&0+5X)R(*D10@T!EN%FGBP+!
MJ )X$@#)4!<0C%AB0D442EX$6-0H49(&%DD0?/\=L.1 =ECPY4F<$:">>@-(
MX6A!'%"H94)*Z7?  6G.MZ&%>3S_0:8 %DHJT)EI'LBF0#?,"1Z<#)&1(G@M
M#O2ACVN%F*R(+"1V8XA_I?"GLB-*  $3>&6K[;9XX3!K"-R&*^ZXW"H555->
M8%G  !;D,898#3! @KL,*+#  D3D\<,"7BU@5A)N G8#'DA $,$#++Q![L(,
M>S22MTL)D$.Z2Q'0;AC\9K45"0QXQ0!8\"H0Q%E^ 78$H2'.U?#*++=<$,#1
M0J"CI*T:0  "R!T4WU+U#:3!EQC9FH=_D&+4A @XY(!#T@EHN!X(.BRM= YP
MQ*KN@05\T$047T31A <Z7.B$DTV)E$>&2PVP:QXWN%EM# G=D-:*<O&91PTQ
MKI6$%EAD_\&W%EGXC87">=PHH@0O*)%$$D7$P(*O@+H@-$1)KNKJY>L%L$.3
M/-N7Q\_Z$<"?05*V6J5,>5R9=H(%=>GI4FDT-*9^ZWEJNX8(?*$J 1D0!*-:
MS;FQ!(@D-MK%L->:03R)+HZ$-[(BJC6G!"SH]2RQ)AXTO(@0+!%DZ$2..M#.
M!KHG4!-D#M ['KJ-!$5^JZJ=$.=9CCX0#U"5+Y"M>LWN(*P*.E/$UN:G-\GD
M!=*:@.0&DB<1%2M.>9N1^%!7N( =:B2ZN8,+YB07N+GL@R#\R$AVD!\#,"5L
MDPNA"E=X%'.M9B44G-1#^,?"&J[0A0) 01K@MYH-Y($-'1L+ _],@) A*& $
M8U' %/)PA9(]P'LIM*$4\?(P"J$K *UBE[LR%J\2P(%C'@,95LCRKY)!X&0E
M4]D4UY@M%UXQ=.T: Q>UPI4@QDN,6!$9R>(" ;>43(%L#*1=,N6: %C@,2)@
M3(%8%Y9[,4 ,>>#" NRE@"'DH0XE4$"]3L"^OD0K H*YP0.LI0+T"/*4@N2+
M&0>&RE9J)(H=@25!ZK""X4! !7,X"$J$E#,!D4])/ON2_0@B)?U@A .'694R
MHZ(J9<8/! *APP5,8CEG*G, 31#(V)19-H2DH7+R,U; Y++ A,2 @R3*GA'R
M%J)I_>5/U/'@C?Y$IP2.B)[.Z<($([+_R_7@+"$[6\IC1@*ZV@T3,LD$T&G:
MEP<"K>Y"[!-(&)RV+M-$=']%\A]3 &@0M,5O;6U3UE\B8(.#'$%1P&/>A>0T
MH@G02%(8',BSU!*!F17D#3T"3YT\N!%(T<<.>%C2'? P5#O8(:"K<@]!D92D
MTQ7$/[1SZD!4ER763>H"3L-,F#0Z@)70@:CL VI5?$I XI%'3B.%8AZTP!RU
MQ""E$K ;WO#)G3L,%:QVO>@\690]@R0J+HS:9T,@M9X!O(8U S")'8H9%<\5
M=#\)@:KI$$(_J6R)('>@@-,.$+ODB$E=-C.L $1#  #P( Y,+<":/&36"0#I
M0\!# O!JF@=A_WU2KGDCE@0BP-O=2N")%[I>G:(CM"7,307=^QXS$6 ^@U#*
MF9X# 9D"X 2$W"$!J3W ; [BT*J*K[(">(+LIHL",VEH-2#%D02 E0<8..<O
M$H ! RW8O+O%B#HT\JSAB*6C@]SA<< +5) JQUR .JEG KGN>:/2A#B,Y YH
MZ,#52F.V[EIV@E(RD-IZX(4TP$$-:@"#%'BPI#$9J&PPS8, 4<*A_;$MM^Q5
M2 ,793<8M?0*;3"#CG5\AAV?823[[2#@^+:$&"!++<WJ"&M&J]CW4"  G"F0
MYP8"!Q"HEC &6A4!1HL!*$4Q P#8<F*_(-@\2 $#JOV,9_)SJ28 0/\T (#A
M07:XY=NT:Z6C) X$!+40,@PG K^U:1Z. &C?5J?0Q0&1LT;96^( FK?,44$,
MM"!+5UHZ6W"0BFH1?.E.3Q%B#I*SIT<=PBI&+#>D3C4(<0BN2JOZU=VBD$KR
M  +7](;,>0B+ NS%!=3II0XDH*0)$J/!!T0  BWHB5Y<#>M6FOI_7J"0Q;;H
ML1(D9@U"",)-\C"#D/UK>;3% QF.< 4Y-/O<)+&B4Z0=QP4@L8MX,(&[1] Q
M/(3EW64Y2\"@\X:2D13=L ;U1J.=MG:_FXY@_$I8^E5&/AH!9?"E"\!)_>R!
ML]M=\$*X'1>0$V_O<2U]A#@Y)ZYJ@=,J71K_;G>UV9#P.]X[CPT'^</GUAR)
MDWS4^.-F$]3 PP!P( ]O\,H(%G""/,A[!.^^ Q&.F$0J[/$OT&D#\9![IYN3
M.@XZZ( .+H6'K\&$(#2AP;;=-8,95&$@.=G)4#PY4L'@(0LV,((;F&UU2]-0
MAN\9B!(")@&WN[CN@.^()V544N=*!);,%EK[%!^FF,;2LQM!/-[QTL28><\@
M7\A\YL&00C1H_@N<'XCG/]_+W7B!]&?[O.I7_WDO5*T@<!@Q#D   A'L  K;
MS4,<3I]Y+^3>('=H_>G>L&,=NZ$A<BA#CW5,.)\4__G/+T-/ZE &Z!>_#4-Q
MR$CD8(08%*'Y!6&5_WH24'IB)G-5CG52 0XJD S09RG'3"@SA<0S:YK/#B#@
M##.M*14+2(B:98(0'B45Z:4"G]0H"K$%[S52]>5G(Q(7$.@CTM(3QP,\T',X
MQ!$#Q_<1D+(JY3<^"64I P%5)R$Z^Y1A"H4!;V9KO4%8K5%( P  XI4ZZI(E
M 0!EB<5FVB1KM3)GYQ5.?6)6([4%"6$&T<,B]856AV,PD'9LO.4 ?'(]@,*$
MQ2&!S<%G&U$S-_.!I_%+G(8?M,-^0P,TAD<@&F95!4$^!W( 4E40$[(4*'80
M&9(DX302(94L\)5?!>$&+058]55 5]@0PO5 ,D$&CV. (*<%'5$Y6VA@T/\5
M3%$5):D%)K:"3 ]E$#V0/FN3$&]X+ARU&UF57M#24J8T$'- 3]%3-R\R+,VA
MAS:2(C355R[&5CZB MF7$943%5R8!T>R?^E7,3$A-"@()@=AB?4C/@4E%1:U
M$!K537)X7JNE%[]C@>UD;@G6(REE*$DX+&J!A69S/>FT3S& (Q&@B!M1?_R'
M  BP*A_0BP9R*0U%39"%$%#55!-D8:?")4TC))W%C/"#$@>0  >@CLJTCCR@
M*JLE3LI"!BT@(TFF'-7Q EN AX1H8W2B BR@ AJID2O0D=9(!NHEBR<2 09(
M(MC24X3%?Y;S!1EP-0/U.378ANTWB3)Y)6<H0Z[_HRK]J! :!9#\-P >H 9.
MDI!!&&!K, <^\@)WPXUW4 ;<&%=M@HI6J!9U4G@5-%O]I2## SS)17<$82 &
MP@$=P %B298:$#9(U3-+%88G2(;%* "YHE7ZN%F_QXGJ0@ ),)9DN9<;D 9J
M\'ZZXCNP^"-Y8(07. 'H85L,>"&_(R(Q4 .0&9DU8 ,Q "1 1I+\E1##0T\1
M<'D:D9)*]7>G@0&;]9(>,"M04AGGQUF&1U7S@88#H2EIDYK^&#'EE6*XPF)E
MA8K XI3((@'<D0=Y$B+%XCR^(D&P-$_2<D$'\3S$D@4#5CE<"!\N>2$Y,%TH
M9!"99B _58;I YL"D4AP_WB;M?D_^Y2;-B.**P(G(Z& *R(!1#@2PXF$ R$G
M^.2*"1%DT&%XQX.(:G&+CP*6B/$>7OB28#  K3(?45",9--J;_E0##510B(
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M \U5$&"0 QJPCEF& 2A@!0R%$$V0 SL@JE33$&'  QY@ <!J 1D@ CS 'V&
MJJ+J% D1!\@:-3Y $%V0!$LPK4I@C0OQ!DHPK4N0!,$Y$&:P!-FJK>(JKDPP
2$FX@K>.JK5B@!68 H!\1$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
